Eugene J. Koay, MD, PhD, MD Anderson Cancer Center

Closing out their discussion on biliary tract cancers, expert panelists share key takeaways and excitement for the evolving treatment paradigm.

Comprehensive insight on novel targeted agents under investigation in the setting of biliary tract cancers.

An overview on novel treatment strategies in biliary tract cancers combining immune checkpoint inhibitors with various targeted agents.

Centering discussion on the TOPAZ-1 trial of chemotherapy in combination with durvalumab, panelists consider how this regimen has impacted clinical practice.

Key opinion leaders in the field of biliary tract cancers highlight mainstay systemic therapy regimens within the treatment paradigm.

A brief discussion on the continued role of liver transplant in biliary tract cancers and when it is appropriate to consider a patient for this procedure.

A comprehensive review of liver-directed therapies available to aid in the management of biliary tract cancers.

Moving on to identify specific treatment modalities, panelists discuss the surgical and perioperative strategies used to manage biliary tract cancers.

Key opinion leaders review the advent of molecular testing in biliary tract cancers and consider its impact on informing treatment decisionmaking.

Focused conversation on the optimal workup and staging of biliary tract cancers within the current paradigm.

Centering focus on a patient scenario, panelists break down mainstay diagnostic strategies used to identify biliary tract cancers.

Expert panelists open their discussion on biliary tract cancers by identifying various subsets and noting the growing incidence of these diseases.

An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.